MAZE
Maze Therapeutics, Inc.$31.38-0.55 (-1.72%)Prev Close$31.93·MCap$1.72B·P/E—·Vol176.1K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
39
$17.97M
◆
Net Activity
Net Seller
$17.97M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at Maze Therapeutics, Inc. (MAZE) has been exclusively selling, with 0 insider purchases totaling $0.00 and 39 insider sales totaling $17.97M. The most recent insider transaction was by Dandekar Atul (officer: CSBO), who sold $240.5K worth of shares on Oct 30, 2026. Maze Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.72B.
MAZE Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $32.07 | $240.5K | 32,316 |
| Oct 2, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $27.02 | $932.3K | 191,447 |
| Oct 2, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 16,141 | $26.93 | $434.7K | 0Exit |
| Oct 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $27.06 | $202.9K | 32,316 |
| Sep 8, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 9,705 | $26.22 | $254.5K | 0Exit |
| Sep 4, 2026 | Dandekar Atul | officer: CSBO | Sell | 6,434 | $26.24 | $168.8K | 35,950 |
| Sep 4, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 10,295 | $26.24 | $270.1K | 15,519-40% |
| Sep 4, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 22,638 | $26.24 | $594.0K | 40,148-36% |
| Sep 4, 2026 | Courtney Phillips | officer: GC and Corp. Secretary | Sell | 3,993 | $26.24 | $104.8K | 9,262-30% |
| Sep 3, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $26.29 | $907.0K | 223,355 |
| Sep 3, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 16,141 | $26.36 | $425.5K | 0Exit |
| Aug 31, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $27.58 | $206.8K | 26,250 |
| Aug 14, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 16,142 | $27.61 | $445.6K | 0Exit |
| Aug 5, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $26.73 | $922.3K | 256,867 |
| Jul 31, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $27.34 | $205.0K | 26,650 |
| Jul 2, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 14,609 | $29.90 | $436.9K | 1,200-92% |
| Jul 2, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $29.98 | $1.03M | 288,768 |
| Jul 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $28.02 | $210.2K | 26,250 |
| Jun 24, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 27,858 | $26.04 | $725.5K | 342,944 |
| Jun 3, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 14,853 | $25.66 | $381.1K | 1,600-90% |
| Jun 3, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 6,643 | $26.20 | $174.0K | 344,897 |
| Jun 2, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $26.34 | $197.6K | 24,808 |
| May 27, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 32,564 | $26.01 | $847.0K | 376,569 |
| May 18, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $26.22 | $393.4K | 0Exit |
| May 18, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 1,938 | $26.00 | $50.4K | 381,073 |
| May 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $25.37 | $190.3K | 10,503-42% |
| Apr 2, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 2,500 | $29.44 | $73.6K | 13,265 |
| Apr 2, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $29.46 | $441.9K | 3,648-80% |
| Apr 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $29.34 | $220.0K | 11,293-40% |
| Mar 20, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $49.10 | $736.4K | 8,839-63% |
| Mar 12, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 30,000 | $50.45 | $1.51M | 348-99% |
| Feb 4, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 5,000 | $46.04 | $230.2K | 17,765 |
| Feb 4, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $46.02 | $690.3K | 14,400-51% |
| Feb 2, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $44.27 | $332.0K | 16,803-31% |
| Jan 26, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 5,000 | $45.52 | $227.6K | 12,965-28% |
| Jan 9, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 25,156 | $40.20 | $1.01M | 0Exit |
| Jan 8, 2026 | Sohn Catherine A. | director | Sell | 29,413 | $39.07 | $1.15M | 0Exit |
| Jan 6, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 5,000 | $39.15 | $195.8K | 15,560 |
| Jan 6, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 4,844 | $40.39 | $195.7K | 0Exit |
| Sep 15, 2025 | SCHELLER RICHARD H | Director | Sell | 20,744 | $22.37 | $464.0K | 0 |
MAZE Insider Buying Activity
The following table shows recent insider purchases of Maze Therapeutics, Inc. (MAZE) stock reported via SEC Form 4 filings.
No insider buying activity found for MAZE in the last 12 months.
MAZE Insider Selling Activity
The following table shows recent insider sales of Maze Therapeutics, Inc. (MAZE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $32.07 | $240.5K | 32,316 |
| Oct 2, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $27.02 | $932.3K | 191,447 |
| Oct 2, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 16,141 | $26.93 | $434.7K | 0Exit |
| Oct 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $27.06 | $202.9K | 32,316 |
| Sep 8, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 9,705 | $26.22 | $254.5K | 0Exit |
| Sep 4, 2026 | Dandekar Atul | officer: CSBO | Sell | 6,434 | $26.24 | $168.8K | 35,950 |
| Sep 4, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 10,295 | $26.24 | $270.1K | 15,519-40% |
| Sep 4, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 22,638 | $26.24 | $594.0K | 40,148-36% |
| Sep 4, 2026 | Courtney Phillips | officer: GC and Corp. Secretary | Sell | 3,993 | $26.24 | $104.8K | 9,262-30% |
| Sep 3, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $26.29 | $907.0K | 223,355 |
| Sep 3, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 16,141 | $26.36 | $425.5K | 0Exit |
| Aug 31, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $27.58 | $206.8K | 26,250 |
| Aug 14, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 16,142 | $27.61 | $445.6K | 0Exit |
| Aug 5, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $26.73 | $922.3K | 256,867 |
| Jul 31, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $27.34 | $205.0K | 26,650 |
| Jul 2, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 14,609 | $29.90 | $436.9K | 1,200-92% |
| Jul 2, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $29.98 | $1.03M | 288,768 |
| Jul 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $28.02 | $210.2K | 26,250 |
| Jun 24, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 27,858 | $26.04 | $725.5K | 342,944 |
| Jun 3, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 14,853 | $25.66 | $381.1K | 1,600-90% |
| Jun 3, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 6,643 | $26.20 | $174.0K | 344,897 |
| Jun 2, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $26.34 | $197.6K | 24,808 |
| May 27, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 32,564 | $26.01 | $847.0K | 376,569 |
| May 18, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $26.22 | $393.4K | 0Exit |
| May 18, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 1,938 | $26.00 | $50.4K | 381,073 |
| May 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $25.37 | $190.3K | 10,503-42% |
| Apr 2, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 2,500 | $29.44 | $73.6K | 13,265 |
| Apr 2, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $29.46 | $441.9K | 3,648-80% |
| Apr 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $29.34 | $220.0K | 11,293-40% |
| Mar 20, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $49.10 | $736.4K | 8,839-63% |
| Mar 12, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 30,000 | $50.45 | $1.51M | 348-99% |
| Feb 4, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 5,000 | $46.04 | $230.2K | 17,765 |
| Feb 4, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $46.02 | $690.3K | 14,400-51% |
| Feb 2, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $44.27 | $332.0K | 16,803-31% |
| Jan 26, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 5,000 | $45.52 | $227.6K | 12,965-28% |
| Jan 9, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 25,156 | $40.20 | $1.01M | 0Exit |
| Jan 8, 2026 | Sohn Catherine A. | director | Sell | 29,413 | $39.07 | $1.15M | 0Exit |
| Jan 6, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 5,000 | $39.15 | $195.8K | 15,560 |
| Jan 6, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 4,844 | $40.39 | $195.7K | 0Exit |
| Sep 15, 2025 | SCHELLER RICHARD H | Director | Sell | 20,744 | $22.37 | $464.0K | 0 |
MAZE Insiders
Similar Stocks to MAZE
MRNA
Moderna, Inc.
$219.87-1.26%
$85.50B
REGN
Regeneron Pharmaceuticals, Inc.
$923.97+12.96%
$83.15B
RVMD
Revolution Medicines, Inc.
$190.97+0.34%
$39.42B
ALNY
Alnylam Pharmaceuticals, Inc.
$164.06-6.11%
$30.46B
UTHR
United Therapeutics Corporation
$601.25+1.30%
$25.15B
INCY
Incyte Corporation
$120.39+2.95%
$23.69B
INSM
Insmed Incorporated
$112.45+0.83%
$21.18B
EXEL
Exelixis, Inc.
$69.81+5.44%
$16.64B